Abstract:Preclinical studies have attributed neuroprotective properties to the antibiotic minocycline. Animal studies and early clinical trials support its use in several neurological diseases. In animal spinal cord injury models, minocycline improved neurological and histological outcomes, reduced neuronal and oligodendroglial apoptosis, decreased microglial activation and reduced inflammation. A single-centre, human, double-blind, randomized, placebo-controlled study of minocycline administration after spinal cord injury was undertaken for the purposes of dose optimization, safety assessment and to estimate outcome changes and variance. Neurological, functional, pharmacological and adverse event outcomes were compared between subjects administered 7 days of intravenous minocycline (n = 27) or placebo (n = 25) after acute traumatic spinal cord injury. The secondary outcome used to assess neurological differences between groups that may warrant further investigation was motor recovery over 1 year using the American Spinal Cord Injury Association examination. Recruitment and analyses were stratified by injury severity and injury location a priori given the expected influence of these on the sensitivity of the motor exam. Minocycline administered at higher than previously reported human doses produced steady-state concentrations of 12.7 µg/ml (95% confidence interval 11.6-13.8) in serum and 2.3 µg/ml (95% confidence interval 2.1-2.5) in cerebrospinal fluid, mimicking efficacious serum levels measured in animal studies. Transient elevation of serum liver enzymes in one patient was the only adverse event likely related to the study drug. Overall, patients treated with minocycline experienced six points greater motor recovery than those receiving placebo (95% confidence interval -3 to 14; P = 0.20, n = 44). No difference in recovery was observed for thoracic spinal cord injury (n = 16). A difference of 14 motor points that approached significance was observed in patients with cervical injury (95% confidence interval 0-28; P = 0.05, n = 25). Patients with cervical motor-incomplete injury may have experienced a larger difference (results not statistically significant, n = 9). Functional outcomes exhibited differences that lacked statistical significance but that may be suggestive of improvement in patients receiving the study drug. The minocycline regimen established in this study proved feasible, safe and was associated with a tendency towards improvement across several outcome measures. Although this study does not establish the efficacy of minocycline in spinal cord injury the findings are encouraging and warrant further investigation in a multi-centre phase III trial. ClinicalTrials.gov number NCT00559494.

Minocycline decreases blood-brain barrier permeability following aneurysmal subarachnoid hemorrhage: a randomized, double-blind, controlled trial

Minocycline Reduces Intracerebral Hemorrhage-Induced Brain Injury

Minocycline Attenuates Brain Edema, Brain Atrophy and Neurological Deficits after Intracerebral Hemorrhage.

Minocycline Protects Against Delayed Cerebral Ischemia after Subarachnoid Hemorrhage Via Matrix Metalloproteinase‐9 Inhibition

Neuroprotection effect of minocycline on early brain injury after subarachnoid hemorrhage in rats

Minocycline Protects Against NLRP3 Inflammasome-Induced Inflammation and P53-Associated Apoptosis in Early Brain Injury after Subarachnoid Hemorrhage

Minocycline in Severe Cerebral Amyloid Angiopathy: A Single-Center Cohort Study

Effect of Statin Treatment on Vasospasm-Related Morbidity and Functional Outcome in Patients with Aneurysmal Subarachnoid Hemorrhage: A Systematic Review and Meta-Analysis

Minocycline in Acute Cerebral Hemorrhage: An Early Phase Randomized Trial

MINocyclinE to Reduce inflammation and blood‐brain barrier leakage in small Vessel diseAse (MINERVA): A phase II, randomized, double‐blind, placebo‐controlled experimental medicine trial

Attenuation of Acute Stroke Injury in Rat Brain by Minocycline Promotes Blood–brain Barrier Remodeling and Alternative Microglia/macrophage Activation During Recovery

Neuroprotection of minocycline by inhibition of extracellular matrix metalloproteinase inducer expression following intracerebral hemorrhage in mice

Abstract TMP110: Minocycline Reduces Hypoxia-mediated BBB Disruption by Protecting TJP Degradation and Promoting Angiogenesis in SHR/SP with Chronic White-matter Injury

Changes In Blood-Brain Barrier Permeability And Expression Of Related Factors In A Rat Model Of Intracerebral Hemorrhage Following Minocycline Treatment

Changes of Blood–Brain Barrier Permeability Following Intracerebral Hemorrhage and the Therapeutic Effect of Minocycline in Rats

Minocycline ameliorates hypoxia-induced blood-brain barrier damage by inhibition of HIF-1α through SIRT-3/PHD-2 degradation pathway

Methylene blue attenuates neuroinflammation after subarachnoid hemorrhage in rats through the Akt/GSK-3β/MEF2D signaling pathway.

Minocycline is Effective in Intracerebral Hemorrhage by Inhibition of Apoptosis and Autophagy.

Minocycline reduces chronic microglial activation after brain trauma but increases neurodegeneration

Monitoring the protective effects of minocycline treatment with radiolabeled annexin V in an experimental model of focal cerebral ischemia.

Results of a phase II placebo-controlled randomized trial of minocycline in acute spinal cord injury